Core Viewpoint - The company, Jinyu Biotechnology Co., Ltd., has announced a share repurchase plan aimed at implementing an employee stock ownership plan or equity incentive, with a total repurchase amount expected to be between 80 million and 160 million RMB [1][2]. Summary by Sections Share Repurchase Plan - The repurchase plan was first disclosed on October 31, 2024, and the implementation period is set for 12 months following the board's approval [1]. - The maximum repurchase price is capped at 10.01 RMB per share, which was later adjusted to 9.98 RMB per share after a cash dividend distribution [1][2]. Progress of Share Repurchase - As of July 31, 2025, the company has repurchased a total of 15.6833 million shares, representing 1.4107% of the total share capital [2]. - The total amount spent on the repurchase is 108.2412 million RMB, with the highest transaction price being 8.97 RMB per share and the lowest at 6.37 RMB per share [2]. Compliance and Future Actions - The company will adhere to relevant regulations and guidelines regarding share repurchase and will make decisions based on market conditions during the repurchase period [2].

Core Viewpoint - The announcement details a change in the equity stake of a major shareholder in Jinyu Biological Technology Co., Ltd., indicating an increase from 10.92% to 11.00% [1]. Group 1: Shareholder Information - The equity change is attributed to the passive increase in shareholding by major shareholders, specifically Inner Mongolia Jinyu Biological Holdings Co., Ltd. and individuals Zhang Chongyu and Zhang Jing [2][3]. - The total shares held by the major shareholders increased from 151,440,568 shares (13.52%) to 151,440,568 shares (13.62%) [2]. Group 2: Compliance and Impact - The equity change does not violate any prior commitments or plans, and it does not trigger mandatory tender offer obligations [1]. - The change in shareholding is not expected to have a significant impact on the company's governance structure or ongoing operations [2].

Core Viewpoint - The company announced a share buyback program, indicating a strategic move to enhance shareholder value and confidence in the company's future performance [2] Group 1: Share Buyback Details - As of July 31, 2025, the company has repurchased a total of 15.6833 million shares [2] - The repurchased shares represent approximately 1.4107% of the company's total share capital [2]

格隆汇8月1日丨生物股份(600201.SH)公布，2025年7月，公司通过上海证券交易所系统以集中竞价交易 方式累计回购公司股份30万股，占公司总股本的比例为0.0270%，成交最高价为8.97元/股，最低价为 8.95元/股，已支付的金额为268.90万元（不含佣金、过户费等交易费用）。截至2025年7月31日，公司 通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份1,568.33万股，占公司总股本的比 例为1.4107%，成交最高价为8.97元/股，成交最低价为6.37元/股，支付的资金总额为10,824.12万元（不 含佣金、过户费等交易费用）。 ...

1.身份类别 | | □控股股东/实际控制人及其一致行动人 | | --- | --- | | 投资者及其一致 | √其他5%以上大股东及其一致行动人 | | | □合并口径第一大股东及其一致行动人（仅适用于无控股股东 | | 行动人的身份 | | | | 、实际控制人） | | | □其他_______________（请注明） | 2.信息披露义务人信息 证券代码：600201 证券简称：生物股份 公告编号：临2025-048 金宇生物技术股份有限公司 关于持股5%以上股东权益变动触及1%刻度的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 权益变动方向 | 比例增加√ | 比例减少□ | | --- | --- | --- | | 权益变动前合计比例 | 10.92% | | | 权益变动后合计比例 | 11.00% | | | 本次变动是否违反已作出的承诺、意向、计划 | 是□ | 否√ | | 是否触发强制要约收购义务 | 是□ | 否√ | 一、信息披露义务人及其一致行动人的基本信息 ...

份有限公司关于以集中竞价交易方式回购公司股份的回购报告书》（公告编号：临 2024-045）。 证券代码：600201 证券简称：生物股份 公告编号：临2025-049 金宇生物技术股份有限公司关于 以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2024/10/31 | | --- | --- | | 回购方案实施期限 | 董事会审议通过后 12 个月 | | 预计回购金额 | 8,000 万元~16,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 万股 1,568.33 | | 累计已回购股数占总股本比例 | 1.4107% | | 累计已回购金额 | 万元 10,824.12 | | 实际回购价格区间 | 6.37 元/股~8.97 元/股 | 金宇生物技术股份有限公司（以下简称"公司"）于 2024 年 10 月 30 日召开第 ...

Group 1 - The core viewpoint indicates that the cattle inventory has dropped to a ten-year low, leading to a three-year upward cycle in beef prices, while raw milk prices have fallen below cost, triggering capacity reduction. Leading companies like Modern Farming are expected to see a profit turning point by 2025 [1] - The livestock industry is entering a deep adjustment period, where high-quality companies with low costs and strong capital chains will stand out, indicating long-term high-quality development potential [1][2] - The investment opportunities in the pig industry are primarily driven by policy measures aimed at controlling new production capacity, which will accelerate the exit of inefficient and high-cost producers, thereby supporting prices [2] Group 2 - The pig industry has entered a stable development phase characterized by "capacity reduction + strong players," with market share redistribution occurring among existing players as low-efficiency and high-cost production gradually gets eliminated [2] - The criteria for high-quality companies are becoming clearer, focusing on low-cost breeding capabilities and sufficient capital reserves to withstand policy changes or price fluctuations [2] - The China Livestock Breeding Index (930707) includes major companies in the livestock sector, reflecting the overall performance of listed companies involved in livestock feed, pharmaceuticals, and breeding [2][3] Group 3 - As of July 31, 2025, the top ten weighted stocks in the China Livestock Breeding Index account for 64.83% of the index, including companies like Muyuan Foods, Wens Foodstuff, and Haida Group [3]

证券代码：300463 证券简称：迈克生物 公告编号：2025-064 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监会指定媒体仔细阅读半年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □适用 √不适用 公司计划不派发现金红利，不送红股，不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 二、公司基本情况 1、公司简介 ■ 2、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ 3、公司股东数量及持股情况 单位：股 ■ 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况 □适用 √不适用 □适用 √不适用 前10名股东及前10名无限售流通股股东因转融通出借/归还原因导致较上期发生变化 □适用 √不适用 公司是否具有表决权差异安排 □是 √否 4、控股股东或实际控制人变更情况 控股股东报告期内变更 □适用 √不适用 公司报告期控股股东未发生变更。 实际控制人报告期 ...

Meeting Overview - The 10th meeting of the 11th Supervisory Board of Beihai Guofa Chuanshan Biological Co., Ltd. was held on July 31, 2025, with all three supervisors participating in the voting [2][5] - The meeting was legally convened and chaired by Mr. Lü Qiujun [2] Audit Institution Appointment - The Supervisory Board approved the proposal to appoint Shanghai Shuhui Accounting Firm (Special General Partnership) as the special audit institution for the company's 2025 A-share issuance to specific targets [3][8] - The appointment does not require submission to the shareholders' meeting for approval [4] Audit Institution Details - Shanghai Shuhui Accounting Firm was established in January 1981 and has undergone several transformations, with its current form established in December 2013 [8] - The firm has provided audit services to 72 listed companies in 2024, with a total audit revenue of 0.81 billion yuan [9] - The firm has a total revenue of 0.683 billion yuan in 2024, with 0.204 billion yuan from securities business [9][10] Voting Results - The proposal received unanimous support from the Supervisory Board, with 3 votes in favor and no opposition or abstentions, representing 100% of the valid voting rights [5] Board Meeting Overview - The 17th meeting of the 11th Board of Directors was also held on July 31, 2025, with all 9 directors participating [21] - The Board approved the proposal to appoint the same audit institution for the 2025 A-share issuance, with a unanimous vote of 9 in favor [32][33] Financing Guarantee - The company agreed to provide a guarantee for its wholly-owned subsidiary, Beihai Guofa Pharmaceutical Co., Ltd., for a loan of 20 million yuan from China Postal Savings Bank [29][34] - The loan term is set for 3 years, and the company will not charge any guarantee fees [34][41] - The total amount of external guarantees before this loan was 0 yuan, and the new guarantee represents 2.58% of the company's audited net assets [44]

Investment Overview - On October 12, 2023, the company approved the establishment of a joint venture with Evonik (China) Investment Co., Ltd. to form "Evonik Blue Biological Technology (Shandong) Co., Ltd." in Huimin County, Shandong Province [2] - The registered capital of the joint venture is RMB 37.5 million, with the company contributing RMB 16.875 million (45%) and Evonik contributing RMB 20.625 million (55%) [2] Termination of Investment - The joint venture and its Qingdao branch will be dissolved and liquidated as per the reconciliation agreement signed on July 31, 2025, due to operational considerations and future business planning [4][5] - The board of directors approved the termination of the investment with a unanimous vote of 5 in favor [5] Reconciliation Agreement Details - The agreement includes the dissolution and liquidation of the joint venture and its Qingdao branch, with both parties agreeing to return relevant patents, technologies, trademarks, and strains to the company [6][8] - A new processing agreement will be signed for continued cooperation in the GHS product field, allowing both parties to independently conduct related business under applicable antitrust laws starting August 1, 2025 [9] Impact on the Company - The dissolution and liquidation of the joint venture are not expected to have a significant adverse impact on the company's operations or financial status [12] - The new agreement framework is anticipated to maintain cooperation in the GHS product area without major disruptions to existing business activities [12]